Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Next Up, Parkinson's: Coalition Against Major Diseases Moves To Link Neurodegenerative Ailments In Database

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The Coalition Against Major Diseases will move to create a database of Parkinson's disease trials after unveiling a similar product for Alzheimer's disease

You may also be interested in...



Sounding The Alarm On The Future Of CNS Drug Development

The drug development paradigm for new central nervous system therapeutics is in need of a thorough reimagining, Tufts Center for the Study of Drug Development researchers assert in an analysis published in Scientific American.

Sounding The Alarm On The Future Of CNS Drug Development

The drug development paradigm for new central nervous system therapeutics is in need of a thorough reimagining, Tufts Center for the Study of Drug Development researchers assert in an analysis published in Scientific American.

Avandia Aftershocks: Will FDA Drug Safety Review Structures Crumble?

Rep. Rosa DeLauro's, D-Conn., hearing on the safety of GlaxoSmithKline's diabetes drug Avandia has ratcheted up the pressure on FDA to make broad reforms of its review structure, but the congresswoman has been careful not to urge a particular course of action for the agency

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS004479

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel